METTL16 and esophageal cancer: High METTL16 expression is associated with poor prognosis in several cancers, including gastric cancer,43, 44, 45 hepatocellular carcinoma,26,46,47 esophageal cancer,48 colorectal cancer,49, 50, 51 lung cancer,32 glioblastoma,52,53 melanoma,54 osteosarcoma,55 breast cancer,56,57 cholangiocarcinoma,58 and leukemia.36